Efficacy & Safety
The Power of ANKTIVA®
ANKTIVA is an interleukin-15 (IL-15) superagonist, which is a type of immunotherapy that causes natural killer and T cells to increase in numbers and become more active without activating immunosuppressive T reg cells.
The efficacy outcome measures for the QUILT 3.032 study were complete response (CR) at any time, defined as negative cystoscopy and urine cytology, and duration of response.
53+ Months
Meaning some study participants
remained NMIBC-free for over 4 years1
+ Denotes an ongoing response
84%
99%
The following dataset reflects an updated follow up of the 77 patients in the ANKTIVA prescribing information demonstrating the durability of response of ANKTIVA plus BCG.1
Kaplan Meier (KM) Duration of Complete Response
69%
95% CI (53/80)
66%
95% CI (50/78)
59%
95% CI (41/72)
51%
95% CI (33/66)
Learn More about Kaplan Meier Duration of Complete Response1
1. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.
Adverse Reactions Occurring in ≥15% of Patients in Cohort A IN QUILT-3.032
| Adverse Reaction | ANKTIVA with BCG1 (n=88) | |
|---|---|---|
| one | two | |
| Dysuria | 32 | 0 |
| Hematuria1 | 32 | 3.4 |
| Urinary | 27 | 0 |
| Micturition Urgency1 | 25 | 0 |
| Urinary Tract Infection1 | 24 | 2.3 |
| Musculoskeletal Pain1 | 17 | 2.3 |
| Chills | 15 | 0 |
| Pyrexia | 15 | 0 |
Clinically relevant adverse reactions in <15% of patients who received ANKTIVA with BCG included fatigue (14%), nausea (14%), bladder irritation (11%), diarrhea (9%), and nocturia (7%).
Efficacy Results in QUILT-3.032
| ANKTIVA with BCG1 (n=88) | |
|---|---|
| Complete Response Rate (95% CI) | 62% (51, 73) |
| Duration of Responsea | |
| Range in months | 0.0, 47.0+ |
| % (n) with duration ≥ 12 months | 58% (28) |
| % (n) with duration ≥ 24 months | 40% (19) |
a. Based on 48 patients that achieved a complete response at any time; reflects period from the time complete response was achieved
Efficacy & Safety
A clinical resource highlighting key efficacy and safety information about ANKTIVA (nogapendekin alfa inbakicept-pmln)
ANKTIVA: How to Order
A step-by-step guide on how to order ANKTIVA, including product codes
Patient Stories
Read about patients who participated in the clinical trials for ANKTIVA
Justin’s Journey
An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope though his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.
Wayne’s Journey
Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people”. When he was first told, “you might have a tumor in your bladder”, he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.
ANKTIVA Resources
Information for ANKTIVA
ANKTIVA: Efficacy & Safety
A clinical resource highlighting key efficacy and safety information about ANKTIVA (nogapendekin alfa inbakicept-pmln)
ANKTIVA: Mechanism of Action
A description of how BCG and ANKTIVA work together in NMIBC CIS
ANKTIVA: How to Order
A step-by-step guide on how to order ANKTIVA, including product codes
Physicians' Journey
Listen to the physicians' journey with their patients using ANKTIVA.
ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG
For more information, please call 1-877-ANKTIVA
